Artificial Intelligence (AI) in Drug Discovery Market Size, Share, Strategic Analysis, Forecast 2030

The artificial intelligence (AI) in drug discovery market focuses on the use of advanced AI and machine learning technologies to accelerate the process of identifying, designing, and developing new drugs. AI models analyze large biological, chemical, and clinical datasets to predict drug-target interactions, optimize molecular structures, and improve success rates in clinical trials—dramatically reducing the time and cost traditionally required for drug development. Market growth is driven by the rising need for efficient drug discovery processes, growing prevalence of chronic and complex diseases, and increasing collaborations between pharmaceutical companies and AI technology providers. Key applications include target identification, lead compound optimization, biomarker discovery, and drug repurposing.

The global artificial intelligence (AI) in drug discovery market size was valued at USD 3.00 billion in 2022 and is projected to grow from USD 3.54 billion in 2023 to USD 7.94 billion by 2030, exhibiting a strong CAGR of 12.2% during the forecast period. The market’s expansion is driven by the increasing integration of AI technologies in pharmaceutical research, which significantly accelerates the drug discovery process, reduces costs, and improves success rates in identifying viable drug candidates. AI algorithms enable researchers to analyze vast biological data sets, predict molecular behavior, and identify novel therapeutic targets with high accuracy. Moreover, the rising prevalence of chronic diseases, growing R&D investments by pharmaceutical and biotechnology companies, and collaborations between AI providers and drug developers are further fueling market growth. North America dominated the AI in drug discovery market with a 69.33% share in 2022, owing to strong technological infrastructure, presence of key AI innovators, and supportive government initiatives promoting digital transformation in healthcare research.

Market Drivers & Restraints

Key Market Drivers

• Efficiency in Drug Discovery: AI reduces the cost and time required for early-stage drug development by predicting molecular behavior and optimizing compound design.

• Rising R&D Investments: Increasing investments by biotechnology and pharmaceutical companies to integrate AI for faster innovation and discovery are fueling market expansion.

• Collaborations & Partnerships: Major players are partnering to enhance AI capabilities for target identification and clinical trial management.

• Advancements in Machine Learning: Continuous progress in deep learning, data analytics, and natural language processing has improved the accuracy of predictive models in drug discovery.

Market Restraints

• Data Privacy & Integration Issues: Limited access to high-quality, standardized data restricts the scalability of AI algorithms.

• High Implementation Costs: Establishing AI infrastructure demands significant financial investment and skilled personnel.

• Regulatory Challenges: Strict regulatory requirements and validation processes for AI-based drug models can delay adoption.

Market Competitive Landscape

The Artificial Intelligence (AI) in Drug Discovery Market is highly competitive with several established and emerging players contributing to technological advancements and innovation. These companies are focusing on mergers, acquisitions, partnerships, and funding to enhance their market presence.

Top Companies in the Market

• Microsoft (U.S.)

• Schrödinger, Inc. (U.S.)

• Cresset (U.K.)

• IBM (U.S.)

• Atomwise Inc. (U.S.)

• Insilico Medicine (U.S.)

• Exscientia (U.K.)

• BenevolentAI (U.K.)

• Aria Pharmaceuticals, Inc. (U.S.)

• Integral BioSciences (U.S.)

• Alphabet Inc. (U.S.)

Companies like Insilico Medicine and Exscientia are at the forefront of generative chemistry and AI-powered molecule design, while Microsoft and IBM provide advanced computing capabilities that accelerate AI adoption in the life sciences sector.

Market Segments

The AI in Drug Discovery Market is segmented based on key parameters as follows:

• By Application: Endocrinology, Cardiology, Oncology, Neurology, and Others

• By Drug Type : Small Molecule and Large Molecule

• By Offering : Software and Services

• By Technology: Machine learning, deep learning, natural language processing, and other AI-based algorithms.

• By End User: Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic institutions.

Among these, the target identification segment accounted for a significant share due to the increasing application of AI in early drug discovery stages to predict molecular interactions effectively.

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/artificial-intelligence-in-drug-discovery-market-105354 

Market Regional Insights

North America dominated the market in 2022 with strong AI adoption across pharmaceutical R&D, supported by key players and advanced digital infrastructure. The region’s focus on AI integration in precision medicine and oncology research is fueling continued dominance.

Europe is anticipated to witness substantial growth, driven by government funding for biotechnology innovation and AI adoption across healthcare research institutions.

Asia Pacific is expected to record the highest growth rate during the forecast period, owing to rising investments in AI-driven pharmaceutical research and expanding biotech sectors in countries like China and India.

Future Market Scope

The AI in drug discovery market holds immense potential as pharmaceutical companies increasingly leverage data-driven insights to accelerate new drug launches and enhance precision medicine. Future growth will be driven by advanced AI models capable of integrating multi-omics data, improving clinical trial outcomes, and minimizing drug development failures.

As more collaborations emerge between AI startups and pharmaceutical giants, the market will continue to evolve towards fully automated drug design platforms. Regulatory acceptance and ethical AI frameworks will further support commercialization, while governments and private investors will continue to fund R&D initiatives for AI-enabled discovery.

Key Industry Development

In November 2022, Cyclica received a USD 1.8 million grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform for developing new non-hormonal contraceptives, leveraging advanced biological data analytics for low-data targets.

Conclusion: The Artificial Intelligence (AI) in Drug Discovery Market represents a transformative shift in the global pharmaceutical industry. As AI technology continues to mature, it promises to revolutionize the discovery, design, and delivery of new therapeutics, paving the way for faster, more precise, and cost-effective healthcare innovation by 2030.

About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com